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Introduction. Hypofractionation is an attractive strategy for dose escalation because of the expected increase in the therapeutic
ratio and logistical convenience for patients and radiotherapy departments. Purpose. To report the preliminary results of IMRT
with hypofractionated SIB for prostate cancer. To describe whether dose distributions using SIB are more optimal than sequential
irradiation of the PTVs.
Methods and materials. Prospective analysis of 25 prostate stage T1c-T3N0-1M0. Hypofractionated IMRT with SIB using 6 MV X-ray
were planned to deliver the prescription dose in 29 fractions. We considered an / of 1.5 for prostate and 3 for organs at risk.
PTV, prescription dose–dose/fraction (Gy): prostate 71.05–2.45; seminal vesicles, 52.2–1.8; lymph nodes 52.2–1.8; involved lymph
nodes, 60.9–2.1; overlap prostate-bladder: 65.25–2.25. Prostate dose was equivalent to 80Gy at 2Gy per fraction. Daily imaging
control using 3 ﬁducial markers implanted in the prostate was used. A CBCT was performed on days 1, 7, 15 and 22. Acute and
late toxicity was prospectively scored (RTOG scale). We made a dosimetric comparison of plans using SIB with sequential PTV
irradiation for 1 of the 3 patients with involved nodes.
Results. Acute genitourinary and intestinal toxicity grade ≥2 was observed in 4/25p and 1/25p respectively. At a median follow-up
of 11 (±6.7) months, late intestinal toxicity ≥2 occurred in 1 patient. Two patients had genitourinary grade 1 toxicity. All cases
were disease free. SIB compared to sequential showed similar conformity and heterogeneity index for the PTV above mentioned,
lower doses in the rectum and bladder and lower volume of normal tissues receiving moderate doses.
Conclusions. Hypofractionated IMRT with SIB enables dose escalation with low rates of toxicity. SIB irradiation dosimetric plan is
slightly better than sequential irradiation plans offering an accelerated approach to treat prostate tumours. Longer follow-up is
necessary to evaluate the efﬁcacy and long-term toxicity of hypofractionated treatments.
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Objective. To report feasibility and evaluate acute toxicity of patients treated with hypofractionation and simultaneous integrated
boost (SIB) with Volumetric Modulated Arc Therapy (VMAT).
Materials/methods. 10 patients with prostate cáncer, were treated for radical intent between March 2012 and October 2012 and all
of whom received androgen suppression. According to D’Amico classiﬁcation, the patients were stratiﬁed in intermediate (60%)
and high risk (40%). On the planning −CT CTV1 and CTV2 were delineated: CTV1 included the prostate, CTV2 consisted on CTV1
plus seminal vesicles. CTVs were expanded (5mm) to generate the planning target volumes (PTV). The prescription was 72Gy to
CTV1 and 60Gy to CTV2. All patients were treated in 30 fractions.
Results.Median agewas 72 andmedianGleason scorewas 7. Themedian follow-upwas 188 days [124–280]. Acute gastro-intestinal
toxicity were: 5/10 Grade G0, 4/10 Grade G1 and 1/10 G2. Genito-urinary toxicity was recorded as follows: 4/10 Grade G0, 5/10 Grade
G1 and 1/10 G2
Conclusions. Moderate hypofractionatioon with SIB and VMAT technique showed to be safe with a good acute toxicity proﬁle.
Longer follow-up and more patients treated with this scheme are needed to assess late toxicity and clinical outcome.
http://dx.doi.org/10.1016/j.rpor.2013.03.489
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Purpose. To present, acute and late toxicity, quality of life (QOL) and early biochemical control of a consecutive series of 69 localized
prostate cancer patients treated with hypofractionated VMAT and IGRT.
Methods. Between May 2011 and June 2012, 69 patients were treated. Doses: 70Gy (2.5Gy/fx) for prostate, 60.2Gy (2.15Gy/fx) for
seminal vesicles and 50.4Gy (1.8Gy/fx) for pelvic lymph nodes. Technique: a single VMAT arc with concomitant boost. IGRT was
made with daily CBCT. Mean patient age was 69.3 yo. Risk group were high 39 (56.5%), intermediate 16 (23.2%) and low 14 (20.3%).
53 patients (77%) were treated with androgenic deprivation. Acute and late toxicity was scored with RTOG criteria, IPSS score
and QoL according manual scoring of QLQC30 and PR25. Biochemical relapse was censored according Phoenix consensus.
